Corporate Strategy

Strategic PlansA corporate development plan must provide a clear path to an organization to achieve their vision.  Life Sciences companies need these plans to effectively plan and execute near term and long term strategies (e.g., portfolio alignment, new market entry, investments, acquisitions, and divestures) especially given that it takes a number of years to develop products in this regulatory environment. A successful strategic plan allows the organization to effectively navigate through the complexities in this global healthcare environment while aligning stakeholders and fulfilling the expectations of shareholders. 

Business plans allow organizations to translate broader strategic plans into operational plans.  These operational plans clearly articulate annual goals, investment requirements, and performance measures.  We have extensive experience in developing actionable strategic and operational plans for Life Sciences companies. 

Therapeutic Area Strategy

BioPharma companies constantly seek opportunities to further strengthen the portfolio within a TA or may want to enter into a new TA as part of portfolio expansion. A good therapeutic area strategy requires a deeper understanding of 1) market drivers including clinical, regulatory, reimbursement, prescriber and patient related factors and 2) what it takes in terms of strategic commitment and resources required to win. We collaborate with clients to develop these TA strategies and strategic roadmaps for long term success.

Market Entry Strategy

Patients around the world could benefit from most BioPharma products. In order to maximize investments into new products, BioPharma companies must develop global and country specific development and commercialization strategies. This process is fairly complex due to the diverse nature of healthcare systems and the fact that development and commercialization requirements vary widely across regions.  Many companies with limited resources seek partnerships to enter into these markets and larger companies with resources still have to optimize them effectively to maximize investment return.  We assist companies with strategic analysis required to evaluate different choices and collaboratively design pathways for successful entry.

Product and Company Valuation

A solid understanding of a product potential allows a BioPharma company to make informed investment decisions.  We take a comprehensive approach to assist clients in evaluating the clinical, regulatory, tech ops, and commercial attractiveness of each asset.  We leverage this information to develop forecasting models to assess demand and likely value creation for shareholders.  We have proprietary valuation tools that provide much deeper insight into the attractiveness of BioPharma investment opportunities (e.g., technologies, products, and companies).

Our state-of-the-art patient flow driven valuation models are ideal for BioPharma companies, venture capital firms, investment banks, and private equity companies to take advantage of.  Our proven approach / models are applied to assessing investment opportunities into life sciences products, technologies, and companies.